Linden Rhoads invests exclusively in early-stage technology and life science spin-outs from Washington. See sector focus, stage focus and contact routes.
Linden Rhoads invests exclusively in early-stage technology and life science spin-outs from Washington State research institutions, primarily targeting check sizes of $250,000 to $500,000 per company [3][6]. Her distinctive thesis focuses on commercializing university discoveries, with a portfolio including notable companies like Vicis (medical devices), Mobisante (ultrasound imaging), and C-SATS (acquired by Johnson & Johnson) [4][9]. As the General Manager of The W Fund, she has backed approximately 19 such spin-outs since the fund's 2013 launch, emphasizing sectors like biotech, cleantech, and information technology [5][9].
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Seattle.
Investors like Linden Rhoads · Full investor directory · Investor access · Company funding database